Brief: Aurinia Settles Patent Litigation With Teva
19/08/2026 21:10
BRIEF-Aurinia Settles Patent Litigation With Teva Aug 19 (Reuters) - Aurinia Pharmaceuticals Inc. AUPH.O:
AURINIA SETTLES PATENT LITIGATION WITH TEVA
AURINIA PHARMACEUTICALS - SETTLES PATENT LITIGATION WITH TEVA OVER GENERIC VOCLOSPORIN IN U.S.
AURINIA PHARMACEUTICALS - TEVA MAY LAUNCH GENERIC VOCLOSPORIN IN U.S. NO EARLIER THAN DECEMBER 7, 2036
AURINIA PHARMACEUTICALS - CONTINUES PATENT LITIGATION AGAINST MULTIPLE GENERIC COMPANIES IN NEW JERSEY
Source text: ID:nBw7yxWMja
Further company coverage: AUPH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aurinia Pharmaceuticals
See all newsBrief: Aurinia Settles Patent Litigation With Teva
Canada's Aurinia Q2 revenue rises on LUPKYNIS sales
Brief: Aurinia Pharmaceuticals Q2 Pretax Profit USD 48.786 Million
Aurinia Pharmaceuticals Inc expected to post earnings of 24 cents a share - Earnings Preview
Brief: Lupkynis Associated With A Statistically Significant 53% Reduction In Risk Of Renal-Related Event Or Death